

**SEE
CELLS**

**CHANGE
LIVES**

Cellvizio®

Q2 & H1 2023 Business Update

July 20, 2023

Disclaimer

- This document has been prepared by Mauna Kea Technologies (the "Company") and is provided for information purposes only.
- The information and opinions contained in this document speak only as of the date of this document and may be updated, supplemented, revised, verified or amended, and such information may be subject to significant changes. Mauna Kea Technologies is not under any obligation to update the information contained herein and any opinion expressed in this document is subject to change without prior notice.
- The information contained in this document has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiary, its advisors and representatives accept no responsibility for and shall not be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.
- This document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates. Investors should not base their investment decision on this information.
- This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Mauna Kea Technologies draws your attention to the fact that as forward-looking statements cannot under any circumstance be construed as a guarantee of the Company's future performance and that the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operate may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Furthermore, even if Mauna Kea Technologies' financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this presentation. A description of those events that may have a material adverse effect on the business, financial position or results of Mauna Kea Technologies, or on its ability to meet its targets, appears in the "Risk Factors" section of Mauna Kea Technologies Universal Registration Document registered with the Autorité des marchés financiers (AMF) on June 28, 2023 under number D-23-0545.
- Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables are therefore not necessarily equal to the sum of the individually rounded figures, amounts or percentages.
- This document does not constitute or form part of an offer to sell or to purchase securities or the solicitation of an offer to purchase securities in the United States of America or in any other jurisdiction. The securities mentioned in this presentation have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under any other legislation of any jurisdiction in the United States of America and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act.

Speakers



Sacha Loiseau, Ph.D.
Chairman and
Chief Executive Officer



Côme de La Tour du Pin
Chief Financial Officer

See Cells. Change Lives.

By creating the first platform to image the human body at the cellular level, we've changed the way physicians **see and treat** their patients



Mission

With Cellvizio®, our advanced cellular imaging platform, we provide partners and providers with cutting edge technologies to transform interventional cancer care

The Future of Cellvizio® is Built on Strong Pillars



Unique and differentiated imaging platform

- Proprietary imaging platform that produces real-time, in vivo images
- Used to identify and target abnormal cells



Strong intellectual property portfolio

- 250+ issued patents
- 20 FDA 510(k) clearances
- CE mark
- Category I CPT® codes in the US



Extensive knowledge of procedures

- Tens of thousands of patient procedures in 20 countries
- >1,000 clinical papers



Strong pipeline of potential strategic partnerships

- Regulatory approvals in > 10 indications
- Existing JV in China with Tasly Pharmaceutical




Long-standing collaborations with industry leaders













- J&J (the Lung Cancer Initiative)
- Telix (the IriS Alliance in Urologic Oncology)



Huge market opportunities




Extensive pipeline of indications for potential strategic partnerships

	APPLICATION	ECOSYSTEM	CLINICAL DEVELOPMENT	REGULATORY APPROVAL	IN MARKET	COMMERCIAL PARTNERSHIP
ONCOLOGY	 PANCREATIC KISTS	#needles #AI		GLOBAL	DIRECT	OPEN
	 ESOPHAGEAL & STOMACH CANCERS	#endoscopy #AI		GLOBAL	DIRECT	OPEN
	 LUNG CANCER	#endoluminal robotics #molecular imaging	 <i>Johnson & Johnson</i>	GLOBAL	DIRECT	OPEN
	 PROSTATE & KIDNEY CANCER	#surgical robotics #molecular imaging	 <i>Telix</i>	GLOBAL		OPEN
	 NEUROLOGIC CANCER	#surgery #navigation		USA		<i>TASLY</i>
IBD/ IBS	 IBD / IBS	#endoscopy		GLOBAL		OPEN

 ONGOING STUDIES  COMPLETED STUDIES

An increasingly sophisticated platform



Cellvizio next-generation advanced platform launched in 2021

Main achievements in the first half of 2023

CORPORATE

Strengthened
Leadership Team

Appointment of a Chief
Operating Officer and a
new Chief Financial
Officer

ACTIVITY

Excellent Business
Performance

Strong acceleration of
sales growth notably in
the US despite sharp
reduction in commercial
footprint

PARTNERSHIP

Delivering on Our
Strategy

Launch of JV with Tasly
in China
Multiple discussions
with potential partners
in other indications

CELLVIZIO

Platform
enhancement

Launch of new features
Preparation of FDA
submission for AI

FINANCIALS

Strong Revenue Growth in Q2 and H1 2023

Q2 2023

+77%

revenue growth driven by a +100% increase in sales in the United States and by licensing revenues from the JV with Tasly


H1 2023

+102%


revenue growth with a €3.3M contribution from licensing revenues from the JV with Tasly

Revenue in Q2 and H1 2023 vs 2022

In thousands of euros




Sales by Segment in Q2 2023



Systems

+93%


Strong growth in the United States and Europe, with 4 systems sold, despite the negative impact from the transfer of Chinese business to the JV with Tasly



Consumables

+40%

Strong acceleration in the US PPU business, up 50% despite fluorescein supply difficulties, with 5 new accounts signed in H1 2023



Services

+5%

Global growth in services and J&J's financial contribution to clinical trials

In thousands of euros

■ Q2 2023

■ Q2 2022


Sales by Geography in Q2 2023



United States

+100%

Excellent momentum in the United States, with sales doubling, driven both by systems and probes, and by the acceleration of the PPU business



EU & RoW

+34%

Business boosted by system sales, including the installation of a Cellvizio at Cork University in Ireland



Asia Pacific

-91%

Impact following transfer of Chinese business to the JV with Tasly

In thousands of euros

■ Q2 2023

■ Q2 2022

OUTLOOK

The Group's priorities



Drive Business Momentum

Intensify the adoption of the next-generation Cellvizio

Increase monthly revenue



Increase Operational Performance

Optimize cost structure

Increase cash runway



Ensure Technological Excellence

Develop new features twice a year

Integrate artificial intelligence for a greater edge



Build High-Value Partnerships

Establish high-profile JV in China

Sign new strategic partnerships

Q&A